97 results
8-K
EX-99.1
PCSA
Processa Pharmaceuticals Inc
30 Jan 24
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
10:46am
nature of the forward-looking statements include, but are not limited to, those risks and uncertainties related to market and other conditions
8-K
EX-10.1
PCSA
Processa Pharmaceuticals Inc
30 Jan 24
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
10:46am
and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business conducted or property owned by it makes … had not been made or such enforcement or setoff had not occurred.
5.17 Independent Nature of Purchasers’ Obligations and Rights. The obligations
424B4
PCSA
Processa Pharmaceuticals Inc
29 Jan 24
Prospectus supplement with pricing info
4:15pm
in nature.
The Common Warrants do not confer any rights of common stock ownership on their holders, such as voting rights or the right to receive … equity financings for 90 days from closing of the offering, subject to certain exceptions.
The nature of the representations, warranties
8-K
i9pnmr qgzm1b0b0uzv9
21 Sep 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:29pm
8-K
5h517jhggfbn3o
24 Mar 22
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-10.1
oi662 byv
24 Mar 22
Entry into a Material Definitive Agreement
4:30pm
424B5
2wpgwmstu esf1zgl0hu
24 Mar 22
Prospectus supplement for primary offering
4:15pm
424B5
ohf3ayf2uy34u4nmd
20 Aug 21
Prospectus supplement for primary offering
4:46pm